Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Samsung launches its “AI in Action Lab” in NYC, giving public high school students hands-on AI experience and tools to prepare for real world innovations.
Gen Z workers are increasingly worried AI could replace their jobs. However, experts say companies are using AI more to assist workers than replace them.
Matt Schultz of CleanSpark discusses Bitcoin mining and AI infrastructure converge, energy demand dynamics, and the company’s position in the evolving market.
Bhavin Shah of ServiceNow discusses how the new Autonomous Workforce AI automates tasks, integrates with Teams and Slack, and boosts workplace efficiency.
Angi is partnering with OpenAI to bring its home services marketplace directly into ChatGPT, allowing users to go from questions to booking local pros.
